YXYoujun Xu

Youjun Xu

*This is an algorithmically generated author record based on publicly available information.

Youjun Xu has a total of 55 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Unveiling optimal molecular features for hERG insights with automatic machine learning

    by Congying Xu, Youjun Xu, Ziang Hu, Xinyi Zhao, Weixin Xie, Weiren Chen, Jianfeng Pei


  • Open Access

    Author Correction: Accelerating discovery of bioactive ligands with pharmacophore-informed generative models

    by Weixin Xie, Jianhang Zhang, Qin Xie, Chaojun Gong, Yuhao Ren, Jin Xie, Qi Sun, Youjun Xu, Luhua Lai, Jianfeng Pei

  • Open Access

    Accelerating discovery of bioactive ligands with pharmacophore-informed generative models

    by Weixin Xie, Jianhang Zhang, Qin Xie, Chaojun Gong, Yuhao Ren, Jin Xie, Qi Sun, Youjun Xu, Luhua Lai, Jianfeng Pei

    Deep generative models have advanced drug discovery but often generate compounds with limited structural novelty, providing constrained inspiration for medicinal chemists. To address this, we develop TransPharmer, a generative model that integrates ligand-based interpretable pharmacophore fingerprints with a generative pre-training transformer (GPT)-based framework for de novo molecule generation. TransPharmer excels in unconditioned distribution learning, de novo generation, and scaffold elaboration under pharmacophoric constraints. Its unique exploration mode could enhance scaffold hopping, producing structurally distinct but pharmaceutically related compounds. Its efficacy is validated through two case studies involving the dopamine receptor D2 (DRD2) and polo-like kinase 1 (PLK1). Notably, three out of four synthesized PLK1-targeting compounds show submicromolar activities, with the most potent, IIP0943, exhibiting a potency of 5.1 nM. Featuring a new 4-(benzo[b]thiophen-7-yloxy)pyrimidine scaffold, IIP0943 also has high PLK1 selectivity and submicromolar inhibitory activity in HCT116 cell proliferation. TransPharmer offers a promising tool for discovering structurally novel and bioactive ligands.


  • Open Access

    RefineScore: Improving Ligand Docking Accuracy and Interpretability by Predicting MDN Corrective Physical Interactions

    by Jinmei Pan, Wei Liu, Jintao Zhu, Jiahan Zhou, Weilin Zhang, Haoyu Lin, Geng Dong, Lirui Lin, Youjun Xu, Jianfeng Pei

    Precisely evaluating the protein-ligand interaction is crucial in drug screening and optimization. There are significant advances in the application of machine learning approaches to developing protein-ligand scoring functions in recent years. However, traditional docking softwares and existing deep-learning methods remain unsolved limitations in terms of pose quality and binding affinity prediction accuracy. Furthermore, machine learning-based scoring functions are hard to generalize to unseen cases due to the scarcity of structure-affinity data, and mostly lack physical interpretability. In this study, we propose RefineScore, which learns the underlying physical laws by the neural network parameterized physical energy terms. In addition, mixed density network (MDN) is introduced to predict the distance likelihoods of van der Waals (vdW) and hydrogen bonding (Hbond) pairs and further correct the classical energy equations for the absolute binding free energy calculation. RefineScore provides a versatile atomic interaction evaluation framework within protein-ligand complexes and is highly interpretable for the key interaction analysis and energy contribution decomposition. By integrating these carefully tailored techniques, RefineScore maintains the advantages of machine learning models while providing physical interpretability and capturing complex interaction patterns. Our evaluation results show that RefineScore has superior scoring and ranking power.


  • Open Access

    Conf-GEM: A geometric information-assisted direct conformation generation model

    by Zhijiang Yang, Youjun Xu, Li Pan, Tengxin Huang, Yunfan Wang, Junjie Ding, Liangliang Wang, Junhua Xiao


  • Open Access

    Accelerating Discovery of Novel and Bioactive Ligands With Pharmacophore-Informed Generative Models

    by Weixin Xie, Jianhang Zhang, Qin Xie, Chaojun Gong, Youjun Xu, Luhua Lai, Jianfeng Pei

    Deep generative models have gained significant advancements to accelerate drug discovery by generating bioactive chemicals against desired targets. Nevertheless, most generated compounds that have been validated for potent bioactivity often exhibit structural novelty levels that fall short of satisfaction, thereby providing limited inspiration to human medicinal chemists. The challenge faced by generative models lies in their ability to produce compounds that are both bioactive and novel, rather than merely making minor modifications to known actives present in the training set. Recognizing the utility of pharmacophores in facilitating scaffold hopping, we developed TransPharmer, an innovative generative model that integrates ligand-based interpretable pharmacophore fingerprints with generative pre-training transformer (GPT) for de novo molecule generation. TransPharmer demonstrates superior performance across tasks involving unconditioned distribution learning, de novo generation and scaffold elaboration under pharmacophoric constraints. Its distinct exploration mode within the local chemical space renders it particularly useful for scaffold hopping, producing compounds that are structurally novel while pharmaceutically related. The efficacy of TransPharmer is validated through two case studies involving the dopamine receptor D2 (DRD2) and polo-like kinase 1 (PLK1). Notably in the case of PLK1, three out of four synthesized designed compounds exhibit submicromolar activities, with the most potent one, IIP0943, demonstrating a potency of 5.1 nM. Featuring a new scaffold of 4-(benzo[b]thiophen-7-yloxy)pyrimidine, IIP0943 also exhibits high selectivity for PLK1. It was demonstrated that TransPharmer is a powerful tool for discovery of novel and bioactive ligands.


  • Exploration on learning molecular docking with deep learning models

    by Qin Xie, Wei Ma, Jianhang Zhang, Shiliang Li, Xiaobing Deng, Youjun Xu, Weilin Zhang

    A deep learning‐powered VS approach combined with two free docking programs are proposed and evaluated for screening an ultra‐large compound library to obtain diverse potential active compounds rapidly and efficiently. We found that it is a practical and transferable strategy to significantly reduce computational cost.Background: Molecular docking‐based virtual screening (VS) aims to choose ligands with potential pharmacological activities from millions or even billions of molecules. This process could significantly cut down the number of compounds that need to be experimentally tested. However, during the docking calculation, many molecules have low affinity for a particular protein target, which waste a lot of computational resources.Methods: We implemented a fast and practical molecular screening approach called DL‐DockVS (deep learning dock virtual screening) by using deep learning models (regression and classification models) to learn the outcomes of pipelined docking programs step‐by‐step.Results: In this study, we showed that this approach could successfully weed out compounds with poor docking scores while keeping compounds with potentially high docking scores against 10 DUD‐E protein targets. A self‐built dataset of about 1.9 million molecules was used to further verify DL‐DockVS, yielding good results in terms of recall rate, active compounds enrichment factor and runtime speed.Conclusions: We comprehensively evaluate the practicality and effectiveness of DL‐DockVS against 10 protein targets. Due to the improvements of runtime and maintained success rate, it would be a useful and promising approach to screen ultra‐large compound libraries in the age of big data. It is also very convenient for researchers to make a well‐trained model of one specific target for predicting other chemical libraries and high docking‐score molecules without docking computation again.


  • Open Access

    miDruglikeness: Subdivisional Drug-Likeness Prediction Models Using Active Ensemble Learning Strategies

    by Chenjing Cai, Haoyu Lin, Hongyi Wang, Youjun Xu, Qi Ouyang, Luhua Lai, Jianfeng Pei

    The drug development pipeline involves several stages including in vitro assays, in vivo assays, and clinical trials. For candidate selection, it is important to consider that a compound will successfully pass through these stages. Using graph neural networks, we developed three subdivisional models to individually predict the capacity of a compound to enter in vivo testing, clinical trials, and market approval stages. Furthermore, we proposed a strategy combing both active learning and ensemble learning to improve the quality of the models. The models achieved satisfactory performance in the internal test datasets and four self-collected external test datasets. We also employed the models as a general index to make an evaluation on a widely known benchmark dataset DEKOIS 2.0, and surprisingly found a powerful ability on virtual screening tasks. Our model system (termed as miDruglikeness) provides a comprehensive drug-likeness prediction tool for drug discovery and development.


  • Open Access

    MolMiner: You Only Look Once for Chemical Structure Recognition

    by Youjun Xu, Jinchuan Xiao, Chia-Han Chou, Jianhang Zhang, Jintao Zhu, Qiwan Hu, Hemin Li, Ningsheng Han, Bingyu Liu, Shuaipeng Zhang, et al.

    Molecular structures are commonly depicted in 2D printed forms in scientific documents such as journal papers and patents. However, these 2D depictions are not machine readable. Due to a backlog of decades and an increasing amount of printed literatures, there is a high demand for translating printed depictions into machine-readable formats, which is known as Optical Chemical Structure Recognition (OCSR). Most OCSR systems developed over the last three decades use a rule-based approach, which vectorizes the depiction based on the interpretation of vectors and nodes as bonds and atoms. Here, we present a practical software called MolMiner, which is primarily built using deep neural networks originally developed for semantic segmentation and object detection to recognize atom and bond elements from documents. These recognized elements can be easily connected as a molecular graph with a distance-based construction algorithm. MolMiner gave state-of-the-art performance on four benchmark data sets and a self-collected external data set from scientific papers. As MolMiner performed similarly well in real-world OCSR tasks with a user-friendly interface, it is a useful and valuable tool for daily applications. The free download links of Mac and Windows versions are available at https://github.com/iipharma/pharmamind-molminer.


  • Open Access

    CavitySpace: A Database of Potential Ligand Binding Sites in the Human Proteome

    by Shiwei Wang, Haoyu Lin, Zhixian Huang, Yufeng He, Xiaobing Deng, Youjun Xu, Jianfeng Pei, Luhua Lai

    Location and properties of ligand binding sites provide important information to uncover protein functions and to direct structure-based drug design approaches. However, as binding site detection depends on the three-dimensional (3D) structural data of proteins, functional analysis based on protein ligand binding sites is formidable for proteins without structural information. Recent developments in protein structure prediction and the 3D structures built by AlphaFold provide an unprecedented opportunity for analyzing ligand binding sites in human proteins. Here, we constructed the CavitySpace database, the first pocket library for all the proteins in the human proteome, using a widely-applied ligand binding site detection program CAVITY. Our analysis showed that known ligand binding sites could be well recovered. We grouped the predicted binding sites according to their similarity which can be used in protein function prediction and drug repurposing studies. Novel binding sites in highly reliable predicted structure regions provide new opportunities for drug discovery. Our CavitySpace is freely available and provides a valuable tool for drug discovery and protein function studies.